Wednesday, June 1, 2016
Wolverine World Wide Inc. (NYSE: WWW)
Wolverine World Wide, Inc. designs, manufactures, sources, markets,
licenses, and distributes footwear, apparel, and accessories. The
company operates through Lifestyle Group, Performance Group, and
Heritage Group segments. It offers casual footwear and apparel;
performance outdoor and athletic footwear and apparel; children’s
footwear; industrial work shoes, boots, and apparel; and uniform shoes
and boots.
Take a look at the 1-year chart of Wolverine (NYSE: WWW) below with added notations:
WWW had been declining rapidly into the end of 2015, but in January the stock began to rally, and then moved into a sideways trading range. While in that sideways move, the stock has formed a common pattern known as a rectangle. A minimum of (2) successful tests of the support and (2) successful tests of the resistance will give you the pattern.
The WWW rectangle pattern has formed a resistance at $20 (red), and a $16.50 support (green). At some point the stock will have to break one of the two levels.
The Tale of the Tape: WWW is trading within a rectangle pattern. The possible long positions on the stock would be either on a pullback to $16.50 or on a breakout above $20. The ideal short opportunity would be on a break below $16.50.
Take a look at the 1-year chart of Wolverine (NYSE: WWW) below with added notations:
WWW had been declining rapidly into the end of 2015, but in January the stock began to rally, and then moved into a sideways trading range. While in that sideways move, the stock has formed a common pattern known as a rectangle. A minimum of (2) successful tests of the support and (2) successful tests of the resistance will give you the pattern.
The WWW rectangle pattern has formed a resistance at $20 (red), and a $16.50 support (green). At some point the stock will have to break one of the two levels.
The Tale of the Tape: WWW is trading within a rectangle pattern. The possible long positions on the stock would be either on a pullback to $16.50 or on a breakout above $20. The ideal short opportunity would be on a break below $16.50.
Incyte Corporation (NASDAQ: INCY)
Incyte Corporation focuses on the discovery, development, and
commercialization of proprietary therapeutics in oncology. It offers
JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers.
Its clinical stage products include ruxolitinib cream, which is in
Phase II clinical trial for the treatment of alopecia areata; and
INCB52793, which is in Phase I/II for the treatment of advanced
malignancies.
Take a look at the 1-year chart of Incyte (NASDAQ: INCY) below with my added notations:
INCY appears to have been forming a base of some kind over the past several months, while also forming a key level of resistance to watch at $85 (red). INCY has already tested that level twice, and it looks like it’s going to do it again soon. A break above that $85 level should lead to higher prices, most likely the $90 level from last year, at minimum.
The Tale of the Tape: INCY has a key level of resistance at $85. A long trade could be entered on a break through that level. However, if you are bearish on the stock, a short trade could be made on any rallies up to $85.
Take a look at the 1-year chart of Incyte (NASDAQ: INCY) below with my added notations:
INCY appears to have been forming a base of some kind over the past several months, while also forming a key level of resistance to watch at $85 (red). INCY has already tested that level twice, and it looks like it’s going to do it again soon. A break above that $85 level should lead to higher prices, most likely the $90 level from last year, at minimum.
The Tale of the Tape: INCY has a key level of resistance at $85. A long trade could be entered on a break through that level. However, if you are bearish on the stock, a short trade could be made on any rallies up to $85.
Retrophin Inc (NASDAQ: RTRX)
Retrophin, Inc., a biopharmaceutical company, focuses on the
development, acquisition, and commercialization of therapies for the
treatment of serious, catastrophic, or rare diseases. Its product line
includes Cholbam, a cholic acid for the treatment of bile acid synthesis
disorders due to single enzyme defects, and for adjunctive treatment of
peroxisomal disorders, such as Zellweger spectrum disorders in patients
who exhibit manifestations of liver disease, steatorrhea, or
complications from decreased fat soluble vitamin absorption; Thiola,
which is indicated for the prevention of cystine stone formation in
patients with severe homozygous cystinuria; and Chenodal, a synthetic
oral form of chenodeoxycholic acid for radiolucent stones in
well-opacifying gallbladders.
Take a look at the 1-year chart of Retrophin (NASDAQ: RTRX) below with my added notations:
RTRX had been in a solid downtrend going into February. However, over the past several months the stock had also created a key level of resistance at $16 (red). A break above that $16 level should mean higher prices for the stock, and last week RTRX finally broke that resistance.
The Tale of the Tape: RTRX broke through its key level of resistance at $16. A long trade could be entered on a pull back down to that level. However, a break back below $16 could negate the forecast for a higher move and would be an opportunity to get short the stock.
Take a look at the 1-year chart of Retrophin (NASDAQ: RTRX) below with my added notations:
RTRX had been in a solid downtrend going into February. However, over the past several months the stock had also created a key level of resistance at $16 (red). A break above that $16 level should mean higher prices for the stock, and last week RTRX finally broke that resistance.
The Tale of the Tape: RTRX broke through its key level of resistance at $16. A long trade could be entered on a pull back down to that level. However, a break back below $16 could negate the forecast for a higher move and would be an opportunity to get short the stock.
Subscribe to:
Posts (Atom)